Why did ENDP discontinue a Phase III clinical trial and return to BNC.TO global rights to the drug in 2012 if it holds blockbuster potential? The trial, designed to compare the drug with another drug not FDA-approved but widely-used off-label, was not recruiting at the expected rate and FDA issues with the trial design could not be resolved. It's a tough space littered with failed clinical trials, one dominated by an existing FDA-approved SOC with 70% success rate, and for which no new drugs have been approved for thirty years. CTSO shareholders beware.
Read booradley's comment posted ahead of yours. He speaks the truth. Zack's just spams for clicks to charge for advertising.
Checking message board history (which I don't encourage - yawn!!), you probably would find a dozen or more people who, over the years, said getting to $1+ would be easy. Don't recall if I just thought it would be easy or publicly expressed the thought and can be counted among those who were very wrong.
Eliminating a material interest in the company may meet one prerequisite, but Kraus would not be able to meet the timeframe requirement to qualify as independent, even if he resigned as Chairman of the Board today.
S&P 500 opened at 1031 and SPPI at $3.90 on July 1, 2010. S&P 500 since is up 194%, and SPPI is up 204%. What bull market runup did SPPI miss?
Two years ago, SPPI's share price was double ITMN's. Today, ITMN's share price is 10X SPPI's. Worse, SPPI's share price is half what it was then. SPPI shareholders have been betting on the wrong horse ... again.
You may have misunderstood. CTSO is forming an audit committee. An audit committee reports to the board of directors. The chair of an audit committee is a member of the board of directors. CTSO is looking to ADD to the board a person with credentials to serve in this capacity. CTSO will not be installing a new board of directors or, as far as we know from what has been communicated to date, appointing a new chairman.
Why would you think the "research" would fall short? Reduction of inflammatory biomarkers in fewer than 150 patients would be the primary endpoint, which already was demonstrated in obtaining the CE Mark.
And what's this about the process being time consuming? Its purpose is to accelerate, not delay, approval. The volume of cardio bypass procedures performed in the US would allow data capture for 150 patients in a very limited timeframe.
Why don't you tell us why you think it would not be considered? Cardio bypass blood filters are Class II devices, CTSO's cartridge is unique, and has demonstrated low risk and known benefits. Those are the requirements for the 510(k) de novo process.
That's not true. I'll repeat my contribution to another (since deleted) thread this morning: Google "nasdaq listing requirements 2014" and click on the "Initial Listing guide for the NASDAQ OMX" pdf link for the truth. Pay particular attention to the three different NASDAQ markets.
mak's post is verbatim from an non-comprehensive Investopedia article and does not take into account the variations in listing criteria between the different NASDAQ markets (Global Select, Global and Capital). Google "nasdaq listing requirements 2014" and click on the "Initial Listing guide for the NASDAQ OMX" pdf link for the truth.
I think much of the concern is on the part of people expecting the share price to run from cents to dollars while they owned hundreds of thousands of shares versus tens of thousands of shares. They will be happy when their tens of thousands of shares are worth $30 instead of $3.
The interplay between IL-6 and TNF-alpha is associated with a number of diseases ranging from pancreatic cancer to schizophrenia and narcolepsy. Several drug candidates in clinical trials have failed attempts to modify the dynamic.
Hey, Yahoo!, I was using that word to mean seize, not female genitals. Your censorship efforts go overboard.